All In Biotech

Drug Trial Radar · NCT05855083

Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA

A Phase 2 Study Evaluating the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Narsoplimab in Pediatric Patients (28 Days to ≤ 18 Years of Age.) With High-Risk Hematopoietic Stem Cell Transplant Thrombotic Microangiopathy

Last checked: Nov 20, 2026Latest source record: Mar 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

18

Planned (sponsor's estimate)

Start

May 1, 2023

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Omeros CorporationIndustry
Sponsor type
Industry
First posted
May 11, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 28 days, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and efficacy of narsoplimab in pediatric patients with thrombotic microangiopathies (TMA) following hematopoietic stem cell transplant (HSCT).

Conditions

  • Thrombotic Microangiopathies
  • Hematopoietic Stem Cell Transplantation

Interventions

  • Biological: narsoplimabDrug

    Treatment with narsoplimab 4 mg/kg will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 100-day survival rate following high-risk HSCT-TMA diagnosis.Time frame: 100 days

Locations

16 sites in 5 countries. Site status is shown where the registry gives one.

  • Omeros Investigational Site

    San Diego, California · Recruiting

  • Omeros Investigational Site

    Gainesville, Florida · Not yet recruiting

  • Omeros Investigational Site

    Boston, Massachusetts · Not yet recruiting

  • Omeros Investigational Site

    St Louis, Missouri · Recruiting

  • Omeros Investigational Site

    New York, New York · Not yet recruiting

  • Omeros Investigational Site

    Valhalla, New York · Recruiting

  • Omeros Investigational Site

    Houston, Texas · Not yet recruiting

  • Omeros Investigational Site

    Seattle, Washington · Not yet recruiting

  • Omeros Investigational Site

    Halle, Germany · Not yet recruiting

  • Omeros Investigational Site

    Hanover, Germany · Not yet recruiting

  • Omeros Investigational Site

    Haifa, Israel · Not yet recruiting

  • Omeros Investigational Site

    Jerusalem, Israel · Not yet recruiting

  • Omeros Investigational Site

    Ramat Gan, Israel · Not yet recruiting

  • Omeros Investigational Site

    Tel Aviv, Israel · Not yet recruiting

  • Omeros Investigational Site

    Utrecht, Netherlands · Not yet recruiting

  • Omeros Investigational Site

    Pamplona, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.